Prostate Cancer
Conditions
Interventions
Gold Standard:The gold standard is the postoperative pathological result, with the specific criteria based on The International Society of Urological Pathology (ISUP) Consensus on Prostate Cancer Grad
Index test:The PSMA-targeted molecular probe 68Ga-DOTA-PSMA-215
Sponsors
Xijing Hospital, Airforce Medical University
Eligibility
Sex/Gender
Male
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Patients: 1. Patients diagnosed with T1-4NxM0 prostate cancer; 2. Scheduled to undergo radical prostatectomy; 3. Male patients aged between 40 and 80 years (inclusive); 4. Life expectancy of more than 12 months as judged by the doctor; 5. Patients and their family members fully understand the patient’s condition and the options of treatment plans, and sign the informed consent form for voluntary participation in the clinical trial.
Exclusion criteria
Exclusion criteria: 1. A history of any previous prostate cancer treatment; 2. Patients with other types of malignant tumors in addition to prostate cancer; 3. Patients with severe pelvic diseases that affect or restrict surgical procedures; 4. Inability to tolerate PET and other imaging examinations (e.g., claustrophobia, radiophobia); 5. Inability to tolerate radical prostatectomy; 6. Severe diseases of the heart, kidneys, lungs, blood vessels, nervous system, or mental health system, as well as immunodeficiency diseases, hepatitis, or liver cirrhosis; 7. Participation in other interventional clinical trials within 1 month prior to screening; 8. Patients currently receiving chemotherapy, immunotherapy, or molecular targeted therapy; 9. Patients who refuse to sign the informed consent form or are unable to cooperate with the study; 10. Other circumstances deemed by the researcher to make the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The diagnostic accuracy of the imaging signals (positive or negative) of prostate cancer lesions for the postoperative histopathological results (positive or negative) of prostate cancer lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactQin weijun; Kang Fei
Xijing Hospital, Airforce Medical University
Outcome results
None listed